Stockscreener 앱 받기
168.42
0.10%
-0.17
시간 외 거래:
168.42
전일 마감가:
$168.59
열려 있는:
$169.31
하루 거래량:
5.09M
Relative Volume:
1.78
시가총액:
$49.98B
수익:
$20.87B
순이익/손실:
$1.50B
주가수익비율:
32.14
EPS:
5.24
순현금흐름:
$2.59B
1주 성능:
-2.20%
1개월 성능:
-4.67%
6개월 성능:
-26.03%
1년 성능:
-29.35%
1일 변동 폭
$168.08
$169.96
1주일 범위
$168.08
$173.44
52주 변동 폭
$163.33
$251.99
벡톤 디킨슨 Stock (BDX) Company Profile
명칭
Becton Dickinson Co
전화
(201) 847-6800
주소
ONE BECTON DR, FRANKLIN LAKES
BDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
168.42 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ISRG
Intuitive Surgical Inc
|
509.36 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
85.40 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
253.68 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
215.82 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
벡톤 디킨슨 Stock (BDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-05-02 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-05-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-05-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2025-05-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-01 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-24 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-05-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-04-12 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-01-03 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-12-12 | 업그레이드 | Citigroup | Sell → Neutral |
| 2022-07-11 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-06-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-03-18 | 재개 | Raymond James | Mkt Perform |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2021-12-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-25 | 개시 | Barclays | Equal Weight |
| 2020-12-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-12-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-07-09 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-06-01 | 재개 | Goldman | Buy |
| 2020-03-05 | 개시 | Citigroup | Neutral |
| 2020-02-07 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-02-07 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-02-07 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-02-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-01-08 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-05-13 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-12-07 | 개시 | Deutsche Bank | Buy |
| 2018-10-16 | 개시 | Barclays | Equal Weight |
| 2018-06-21 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-04-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-01-19 | 재개 | BofA/Merrill | Buy |
| 2018-01-05 | 업그레이드 | Citigroup | Sell → Neutral |
| 2018-01-05 | 개시 | KeyBanc Capital Mkts | Overweight |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2017-12-29 | 재확인 | Deutsche Bank | Buy |
모두보기
벡톤 디킨슨 주식(BDX)의 최신 뉴스
YieldBoost Becton, Dickinson From 2.5% To 15.5% Using Options - Nasdaq
BD upgrades laboratory in Suzhou - China Daily
Becton Dickinson’s SWOT analysis: medical giant’s stock faces pivotal shift - Investing.com
Becton Dickinson’s SWOT analysis: medical giant’s stock faces pivotal shift By Investing.com - Investing.com India
Becton Dickinson Stock Price, Quotes and Forecasts | NYSE:BDX - Benzinga
Medical technology firm BD looks to bring products to more PHL hospitals - BusinessWorld Online
Becton Dickinson at Goldman Sachs Conference: Strategic Moves Ahead By Investing.com - Investing.com South Africa
Becton Dickinson at Goldman Sachs Conference: Strategic Moves Ahead - Investing.com Australia
Becton, Dickinson And Co To Present At Goldman Sachs Conference; Webcast At 2:00 PM ET - Nasdaq
Stifel maintains Becton Dickinson stock with a $224 target - Investing.com
Here's How You Can Earn $100 In Passive Income By Investing In Becton Dickinson Stock - Yahoo Finance
Barclays Lowers Becton, Dickinson & Co. (BDX) Price Target, Maintains Overweight Rating - MSN
Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment - GlobeNewswire Inc.
BD’s Future Plans: Shed Life Sciences to Fund Medical Technology - Lab Manager
How Is Becton, Dickinson and Company’s Performance Compared to Other Medical Instruments & Supplies Stocks? - Barchart.com
Becton Dickinson (BDX) Maintains Overweight Rating Despite Price Target Cut | BDX Stock News - GuruFocus
Barclays lowers Becton Dickinson stock price target to $241 By Investing.com - Investing.com South Africa
Barclays Adjusts Price Target on Becton, Dickinson and Company to $241 From $261 - marketscreener.com
Barclays lowers Becton Dickinson stock price target to $241 - Investing.com
Becton Dickinson (BDX) Receives Adjusted Price Target from Barcl - GuruFocus
Becton Dickinson and : BD Vascular Access Management Recognized with Seal of Approval from Infusion Nurses Society - marketscreener.com
Becton Dickinson (BDX) Receives Adjusted Price Target from Barclays | BDX Stock News - GuruFocus
Becton Dickinson EVP David Shan Sells Shares and Other Important Updates - TradingView
Insider Sell: David Shan Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus
BD to Present at Goldman Sachs 46th Annual Global Healthcare Conference - Quantisnow
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - GlobeNewswire
Becton, Dickinson and Company to Initiate Real-World Patient Data Registry for the Rotarex?? Atherectomy System in Treatment of Peripheral Artery Disease - marketscreener.com
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease - Becton Dickinson
Becton Dickinson’s SWOT analysis: stock’s future hangs on life sciences spin-off - Investing.com
Saudi Arabia Research Antibodies Market Report 2025-2030, - GlobeNewswire
Saudi Arabia Research Antibodies Market Report 2025-2030, Competitive Analysis of Cell Signaling Technology, Salima Trading, AJ Jeel Medical & Trading Co, Becton, Dickinson and Co, and Merck - Yahoo Finance
AC Health, Becton Dickinson team up to elevate healthcare standards across Asia - Bilyonaryo Business News
Becton Dickinson stock rating cut by Citi to Neutral, target to $185 - Investing.com India
Becton, Dickinson & Co (BDX) Is Paying a $85M Settlement to Investors — Here’s How to Get Your Share - TradingView
Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Becton Dickinson (BDX) Receives Downgrade and Price Target Cut b - GuruFocus
Becton Dickinson (BDX) Receives Downgrade and Price Target Cut by Citigroup | BDX Stock News - GuruFocus
6 Analysts Have This To Say About Becton Dickinson - Benzinga
Becton Dickinson (BDX) Downgraded by Citi to Neutral | BDX Stock News - GuruFocus
Becton Dickinson (BDX) Downgraded by Citi Amid Quarterly Challen - GuruFocus
Becton Dickinson (BDX) Downgraded by Citi Amid Quarterly Challenges | BDX Stock News - GuruFocus
Citigroup Downgrades Becton Dickinson and Co. to Neutral From Buy, Adjusts PT to $185 From $217 - marketscreener.com
BD aims to secure slice of medical technology market - BusinessMirror
Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs' - BD Newsroom
Employees return to work at North Canaan plant where suspicious package was delivered, officials say - CT Insider
FBI probes North Canaan suspicious package that contaminated hundreds: What we know and don't know - CT Insider
Becton, Dickinson and Company Stock: Analyst Estimates & Ratings - inkl
Becton, Dickinson and Company (BDX): Among the Most Oversold Stocks to Buy According to Billionaires - Insider Monkey
Health dept. clears BD to reopen facility after hazmat scare - The Lakeville Journal
Argus Adjusts Price Target on Becton Dickinson and Co. to $220 From $270, Maintains Buy Rating - marketscreener.com
벡톤 디킨슨 (BDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
0.98%
자본화:
|
볼륨(24시간):